Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial
出版年份 2020 全文链接
标题
Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial
作者
关键词
-
出版物
DIABETOLOGIA
Volume 63, Issue 3, Pages 473-485
出版商
Springer Science and Business Media LLC
发表日期
2020-01-02
DOI
10.1007/s00125-019-05065-8
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Canagliflozin review – safety and efficacy profile in patients with T2DM
- (2019) Haroon Jakher et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
- (2019) Bernard Zinman et al. Lancet Diabetes & Endocrinology
- Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy
- (2019) Anja Schork et al. Cardiovascular Diabetology
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Weight loss variability with SGLT2 inhibitors and GLP‐1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities
- (2019) Emily Brown et al. Obesity Reviews
- Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
- (2019) M.S. Capehorn et al. DIABETES & METABOLISM
- Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial
- (2019) Ildiko Lingvay et al. Lancet Diabetes & Endocrinology
- Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial
- (2018) Helena W Rodbard et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
- (2018) Richard E Pratley et al. Lancet Diabetes & Endocrinology
- Association between insulin resistance and the development of cardiovascular disease
- (2018) Valeska Ormazabal et al. Cardiovascular Diabetology
- 8. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes—2019
- (2018) DIABETES CARE
- Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETOLOGIA
- Glucagon-Like Peptide-1 Infusion Suppresses Aldosterone Levels in Healthy Normal-Weight Individuals: Double-Blind, Placebo-Controlled Crossover Study
- (2018) Maja Baretić et al. Diabetes Therapy
- Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes
- (2017) Akio Ohta et al. EXPERT OPINION ON PHARMACOTHERAPY
- Effects of Weight Loss on Lean Mass, Strength, Bone, and Aerobic Capacity
- (2017) EDWARD P. WEISS et al. MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
- Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
- (2017) Bo Ahrén et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
- (2017) Christopher Sorli et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
- (2017) Vanita R Aroda et al. Lancet Diabetes & Endocrinology
- Changes in muscle strength after diet-induced weight reduction in adult men with obesity: a prospective study
- (2017) Bokun Kim et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks
- (2016) Lawrence Blonde et al. POSTGRADUATE MEDICINE
- Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
- (2015) Luc Van Gaal et al. DIABETES CARE
- GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond
- (2015) Donna Ryan et al. Obesity
- SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
- (2015) Jochen Seufert Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Obesity, insulin resistance and comorbidities ? Mechanisms of association
- (2014) Ana Valeria B. Castro et al. Arquivos Brasileiros de Endocrinologia e Metabologia
- Lean Tissue Imaging
- (2014) Carla M. M. Prado et al. JOURNAL OF PARENTERAL AND ENTERAL NUTRITION
- World Medical Association Declaration of Helsinki
- (2013) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests
- (2011) Frank Bretz et al. BIOMETRICAL JOURNAL
- Assessment methods in human body composition
- (2009) Seon Yeong Lee et al. CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE
- Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
- (2009) R. A. DeFronzo et al. DIABETES CARE
- Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue
- (2009) J. Jendle et al. DIABETES OBESITY & METABOLISM
- The Impact of Weight Gain on Motivation, Compliance, and Metabolic Control in Patients with Type 2 Diabetes Mellitus
- (2009) F. Xavier Pi-Sunyer POSTGRADUATE MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now